Journals / Cukurova Medical Journal / 2022 / Cilt: 47 - Sayı: 3

Comparison of prolactin level, sexual function, body mass index, and liver function tests in patients using depot antipsychotics

Depo antipsikotik kullanan hastalarda prolaktin düzeyi, cinsel fonksiyon, vücut kitle indeksi ve karaciğer fonksiyon testlerinin karşılaştırılması

Pages
1172–1178
Publication Date
2022-10-12
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Further researches should be conducted on the effects of long-acting antipsychotic use on both prolactin values and other laboratory parameters.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Purpose: In this study, it was aimed to compare sexual dysfunctions, body mass index, liver function tests and prolactin levels in patients using long-acting antipsychotic drug forms (depot paliperidone palmitate, risperidone depot and zuclopenthixol depot).
📊
Key Findings & Data:Results: 95 patients were included in the study.
💡
Conclusion & Impact:Further researches should be conducted on the effects of long-acting antipsychotic use on both prolactin values and other laboratory parameters.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Purpose: In this study, it was aimed to compare sexual dysfunctions, body mass index, liver function tests and prolactin levels in patients using long-acting antipsychotic drug forms (depot paliperidone palmitate, risperidone depot and zuclopenthixol depot). Materials and Methods: Patients diagnosed with schizophrenia and receiving long-acting antipsychotic therapy were included in this study. Demographic data form, Positive and Negative Syndrome Scale (PANSS), Calgary Depression in Schizophrenia Scale (CDSS), and Arizona Sexual Experiences Scale (ASEX) were administered to all participants. Venous blood samples were obtained from all participants to evaluate urea, creatinine, liver function tests, cholesterol and prolactin levels. Results: 95 patients were included in the study. Of those included, 79 (83.2%) were men and 16 (16.8%) were women. The mean age of all patients was 36.77±10.24 years. The mean body mass index was 27.06±4.95 kg/m2. There was no difference between the groups in terms of ASEX and CDSS scores. The prolactin level was found to be higher in patients using paliperidone depot than in patients using zuclopenthixol depot. Conclusion: According to our results, prolactin values that affect sexual functions should be considered in patients using long-acting antipsychotics, even if the patients do not show any symptoms. Further researches should be conducted on the effects of long-acting antipsychotic use on both prolactin values and other laboratory parameters.

Özet

Amaç: Bu çalışmada uzun etkili antipsikotik ilaç formları (uzun etkili paliperidon palmitat, risperidon depo ve zuklopentiksol depo) kullanan hastalarda cinsel işlev bozuklukları, vücut kitle indeksi, karaciğer fonksiyon testleri ve prolaktin düzeylerinin karşılaştırılması amaçlanmıştır. Gereç ve Yöntem: Bu çalışmaya şizofreni tanılı ve uzun etkili antipsikotik tedavisi alan hastalar dahil edildi. Tüm katılımcılara demografik veri formu, Pozitif ve Negatif Sendrom Ölçeği (PANSS), Calgary Şizofrenide Depresyon Ölçeği (CŞDÖ) ve Arizona Cinsel Yaşantılar Ölçeği (ACYÖ) uygulandı. Ardından üre, kreatinin, karaciğer fonksiyon testleri, kolesterol ve prolaktin düzeylerini değerlendirmek için venöz kan örnekleri alındı. Bulgular: Çalışmaya 95 hasta dahil edildi. Dahil edilenlerin 79’u erkek (%83.2) ve 16’sı kadındı (%16.8). Tüm hastaların yaş ortalaması 36.77±10.24 yıl idi. Vücut kitle indeksleri ortalaması ise 27.06±4.95 kg/m2 idi. Gruplar arasında ACYÖ ve CŞDÖ skorları açısından farklılık saptanmadı. Prolaktin değeri paliperidon depo kullanan hastalarda zuklopentiksol depo kullanan hastalardan yüksek olarak hesap edilmiştir. Sonuç: Sonuçlarımıza göre cinsel işlevleri etkileyen prolaktin değerleri, hastalar semptom belirtmese de uzun etkili antipsikotik kullanan hastalarda göz önünde bulundurulmalıdır. Uzun etkili antipsikotik kullanımının hem prolaktin değerleri hem de diğer laboratuvar parametrelerine olan etkileri konusunda ileri araştırmalar yapılmalıdır.

🔖

Cite This Article

TAŞÇI, G., ÖZSOY, F. (2022). Comparison of prolactin level, sexual function, body mass index, and liver function tests in patients using depot antipsychotics. Cukurova Medical Journal, Cilt: 47 - Sayı: 3, 1172–1178. https://ajindex.com/articles/476743

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (15)

  1. Öztürk O, Uluşahin N. Ruh Sağlığı ve Bozuklukları
  2. Baskı. Ankara: Nobel Tıp Kitapevi; 2015;89-261
  3. Gaebel W, Zielasek J. Schizophrenia in 2020: Trends in diagnosis and therapy. Psychiatry Clin Neurosci. 2015;69:661-73
  4. Sacchetti E, Grunze H, Leucht S, Vita A. Longacting injection antipsychotic medications in the management of schizophrenia. Evid Based Psychiatr Care. 2015;1:27-36
  5. Miyamoto S, Wolfgang Fleischhacker W. The use of long-acting injectable antipsychotics in schizophrenia. Curr Treat Options Psychiatry. 2017;4:117-26
  6. Olivares JM, Pinal B, Cinos C. Comparisons of long- acting antipsychotics injection and oral antipsychotics in schizophrenia. Neuropsychiatry. 2011;1:275-89
  7. Lingjærde O, Ahlfors UG, Bech P, Dencker SJ, Elgen K. The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychatr Scand. 1987;334:1-100
  8. Adams CE, Fenton MK, Quraishi S, David AS. Systematic meta-review of depot antipsychotic drugs for people with schizophrenia. Br J Psychiatry. 2001;179:290-99
  9. İnanç L, Özdemir AD, Güleç H, Semiz ÜB. Şizofreni ve bipolar bozukluk hastalarında depo antipsikotik kullanmanın etkinliği ve güvenirliği. Cukurova Med J. 2018;43:38-43
  10. Hayhurst KP, Drake RJ, Massie JA, Dunn G, Barnes TRE, Jones PB, et al. Improved quality of life over one year is associated with improved adherence in patients with schizophrenia. Eur Psychiatry. 2014;29:191-6
  11. Sathienluckana T, Tiangpattanawong P, Chaiyasukthananoan K, Jittayanan P, Sawetwangsing H, Puchsaka P. Comparison of efficacy and safety between long-acting injectable antipsychotic monotherapy and combination of long-acting injectable and oral antipsychotics in patients with schizophrenia. Schizop Res Treat. 2021;2021:8403986
  12. Şafak Y, Bulut SD, Karadağ H, Örsel S. Psikotik bozukluk tanılı hastalarda uzun etkili, oral ve kombinasyon antipsikotik tedavilerinin değerlendirilmesi. Klinik Psikiyatri Derg. 2020;23:72- 82
  13. Taylor D. Psychopharmacology and adverse effects of antipsychotic longacting injections: a review. Br J Psychiatry 2009;52:13-9
  14. Aggarwal NK, Sernyak MJ, Rosenheck RA. Prevalence of concomitant oral antipsychotic drug use among patients treated with long-acting, intramuscular, antipsychotic medications. J Clin Psychopharmacol. 2012;32:323-8
  15. De Berardis D, Vellante F, Olivieri L, Rapini G, De Lauretis I, Orsolini, L, Valchera A e